Donanemab vs Trastuzumab

Donanemab vs Trastuzumab: Overview

This comparison examines the pharmacological differences between Donanemab and Trastuzumab.

Mechanism of Action

Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

Pharmacokinetics

Half-life: Trastuzumab — 28 days.

Chemical Properties

Type: Donanemab — Antibody; Trastuzumab — Antibody.